anti-Potassium Channel, Subfamily V, Member 2 (KCNV2) Anticorps

Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. De plus, nous expédions KCNV2 Protéines (4) et beaucoup plus de produits pour cette protéine.

afficher tous les anticorps Gène GeneID UniProt
KCNV2 169522 Q8TDN2
KCNV2 240595 Q8CFS6
KCNV2    
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top anti-KCNV2 Anticorps sur anticorps-enligne.fr

Showing 10 out of 67 products:

Catalogue No. Reactivité Hôte Conjugué Application Images Quantité Fournisseur Livraison Prix Détails
Humain Lapin Inconjugué WB WB Suggested Anti-KCNV2 Antibody Titration:  0.2-1 ug/ml  ELISA Titer:  1:1562500  Positive Control:  293T cell lysate 100 μL Connectez-vous pour afficher 2 to 3 Days
$289.00
Détails
Humain Lapin Inconjugué ELISA, WB Western blot analysis of extracts from MCF-7 cells, using KCNV2 Antibody. The lane on the right is treated with the synthesized peptide. 100 μg Connectez-vous pour afficher 2 to 3 Days
$302.50
Détails
Humain Lapin Inconjugué IHC (p), WB KCNV2 Antibody (C-term)  western blot analysis in 293,K562,HepG2,Jurkat,ZR-75-1 cell line lysates (35ug/lane).This demonstrates the KCNV2 antibody detected the KCNV2 protein (arrow). KCNV2 Antibody (C-term) immunohistochemistry analysis in formalin fixed and paraffin embedded human pancreas tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of KCNV2 Antibody (C-term) for immunohistochemistry.  Clinical relevance has not been evaluated. 400 μL Connectez-vous pour afficher 10 to 11 Days
$335.50
Détails
Humain Lapin Inconjugué EIA, IHC (p), WB Immunohistochemistry analysis in formalin fixed and paraffin embedded human pancreas tissue reacted with KCNV2 Antibody (C-term) followed by peroxidase conjugation of the secondary antibody and DAB staining. Western blot analysis of KCNV2 Antibody (C-term) in 293, K562, HepG2, Jurkat, ZR-75-1 cell line lysates (35ug/lane). This demonstrates the KCNV2 antibody detected the KCNV2 protein (arrow). 0.4 mL Connectez-vous pour afficher 6 to 8 Days
$390.50
Détails
Humain Lapin Inconjugué ELISA, WB 100 μL Connectez-vous pour afficher 16 Days
$181.73
Détails
Humain Lapin Inconjugué WB 50 μg Connectez-vous pour afficher 7 to 9 Days
$551.83
Détails
Humain Lapin Inconjugué ELISA, WB 50 μg Connectez-vous pour afficher 2 to 3 Days
$446.88
Détails
Humain Lapin Inconjugué WB KCNV2 antibody used at 1 ug/ml to detect target protein. 50 μg Connectez-vous pour afficher 2 to 3 Days
$473.93
Détails
Humain Lapin Alexa Fluor 350 IF (p)   100 μL Connectez-vous pour afficher 14 to 21 Days
$405.90
Détails
Humain Lapin Alexa Fluor 488 IF (p)   100 μL Connectez-vous pour afficher 14 to 21 Days
$405.90
Détails

KCNV2 Anticorps par réactivité, application, clonalité et conjugué

Attributs Application Hôte Clonalité Conjugué
Human , , , ,


, , , , , , , , , , , , , , , ,
Mouse (Murine) , ,


, , , , , , , , , , , , ,
Rat (Rattus) , ,


, , , , , , , , , , , , ,

Plus d’anticorps contre KCNV2 partenaires d’interaction

Human Potassium Channel, Subfamily V, Member 2 (KCNV2) interaction partners

  1. Pharmacogenetic and case-control study evaluated the role of the variants of KCNA1 (Montrer KCNA1 Anticorps), KCNA2 (Montrer KCNA2 Anticorps), and KCNV2 in the susceptibility and drug resistance of genetic generalized epilepsies and revealed no significant association between 8 variants of KCNA1 (Montrer KCNA1 Anticorps), KCNA2 (Montrer KCNA2 Anticorps), and KCNV2 genes and risk or drug resistance of genetic generalized epilepsies after a Bonferroni correction for multiple comparisons.

  2. This is the first report of genetic and clinical analysis of cone dystrophy with supernormal rod response in the Israeli population leading to the identification of 4 novel KCNV2 mutations.

  3. Compound heterozygosity for the two alleles of KCNV2, p.C177R and p.G461R, in three patients, and homozygosity for complex alleles, p.R27H and p.R206P, in one patient from the consanguineous family, is reported.

  4. Central vision parameters progressively worsen in KCNV2 cone dystrophy, structural retinal and lipofuscin accumulation abnormalities are commonly present and macular cone photoreceptor mosaic is markedly disrupted early in the disease.

  5. KCNV2 mutations cause a unique form of retinal disorder illustrating the importance of K(+)-channels for the resting potential, activation and deactivation of photoreceptors, while phototransduction remains unchanged

  6. important finding leading to identification of KCNV2 as a candidate gene for causative mutations was the characteristic pattern of findings on full field ERGs.

  7. two pore mutations (W467G and G478R) led to the formation of nonconducting heteromeric Kv2.1 (Montrer KCNB1 Anticorps)/Kv8.2 channels

  8. For all patients, KCNV2 sequencing revealed one of three homozygous recessive mutations

  9. In this study, we found that KCNV2 mutations are present in a substantial fraction (2.2-4.3%) of a sample of 367 independent patients with a variety of initial clinical diagnoses of cone malfunctino.

  10. In KCNV2 retinopathy foveal morphological changes are evident on SD-OCT (Montrer Plxna2 Anticorps) even in the early stages of disease.

Mouse (Murine) Potassium Channel, Subfamily V, Member 2 (KCNV2) interaction partners

  1. We conclude that nucleotide changes in evolutionary conserved crx (Montrer CRX Anticorps) binding site could impact retina-specific expression levels of Kcnv2.

  2. two pore mutations (W467G and G478R) led to the formation of nonconducting heteromeric Kv2.1 (Montrer KCNB1 Anticorps)/Kv8.2 channels

  3. Results demonstrate that altered potassium subunit function influences epilepsy susceptibility and implicate Kcnv2 as an epilepsy gene.

  4. Data show that total Kv11.1 alpha subunit (Montrer POLG Anticorps) protein is more abundant in neonatal heart and is distributed throughout both adult and neonatal ventricles with greater abundance in epicardia.

  5. Kcnv2 is a strong functional candidate for epilepsy modifier.

KCNV2 profil antigène

Profil protéine

Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium voltage-gated channel subfamily V. This member is identified as a 'silent subunit', and it does not form homomultimers, but forms heteromultimers with several other subfamily members. Through obligatory heteromerization, it exerts a function-altering effect on other potassium channel subunits. This protein is strongly expressed in pancreas and has a weaker expression in several other tissues.

Gene names and symbols associated with KCNV2

  • potassium voltage-gated channel modifier subfamily V member 2 (KCNV2) anticorps
  • potassium channel, subfamily V, member 2 (Kcnv2) anticorps
  • Kv8.2 anticorps
  • KV11.1 anticorps
  • RCD3B anticorps

Protein level used designations for KCNV2

potassium voltage-gated channel subfamily V member 2 , voltage-gated potassium channel subunit Kv8.2

GENE ID SPECIES
169522 Homo sapiens
240595 Mus musculus
Fournisseurs de qualité sélectionnés pour anti-KCNV2 (KCNV2) Anticorps
Avez-vous cherché autre chose?